Phthalonitrile is a precursor for the synthesis of phthalocyanine dyes
**Background**
Phthalocyanines are a class of macrocyclic compounds known for their intense color and exceptional stability, making them invaluable in various scientific and industrial applications. These compounds are widely utilized in the development of dyes, pigments, and advanced materials for optoelectronics and photodynamic therapy. Due to their ability to coordinate with various metal ions, phthalocyanines exhibit unique electronic and spectroscopic properties that are essential for biomedical research and chemical sensing. The synthesis of these macrocycles typically requires specific precursors that can undergo cyclotetramerization. In this context, we will introduce a key synthetic building block – Phthalonitrile.
**Definition**
Phthalonitrile (O-Phthalonitrile) is a chemical precursor used primarily for the synthesis of phthalocyanine dyes. It is characterized by the Phthalonitrile formula C8H4N2 and has a molecular weight of 128.13.
**Chemical Applications**
According to the Phthalonitrile description, this compound serves as the fundamental starting material for creating complex macrocyclic structures. In synthetic chemistry, phthalonitrile is reacted with metal salts to produce metal-phthalocyanines. For instance, research into deformed phthalocyanines has utilized this precursor to synthesize zinc phthalocyanines bearing phenyl substituents at specific positions, such as the 1-, 4-, 8-, 11-, 15-, 18-, 22-, and/or 25-positions. Such modifications allow researchers to tune the solubility and electronic properties of the resulting dyes for specific applications. For those seeking detailed Phthalonitrile technical information regarding its application in the synthesis of zinc-based macrocycles, these derivatives have been extensively characterized for their structural and spectroscopic properties. In conclusion, Phthalonitrile is an essential precursor for the synthesis of phthalocyanine dyes and their functionalized derivatives.
Keywords
Phthalonitrile, 91-15-6, O-Phthalonitrile, Drug Intermediate, Drug Iintermediate, Inhibitor, inhibitor, inhibit
References
**Background**
Liver fibrosis is a pathological response to chronic liver injury, characterized by the excessive accumulation of extracellular matrix proteins. A central event in this process is the activation of hepatic stellate cells (HSCs), which transform into myofibroblast-like cells that secrete collagen and other pro-fibrotic factors. Transforming growth factor-beta (TGF-β) is a primary driver of this activation, making the TGF-β signaling pathway a critical target for therapeutic intervention. Beyond fibrosis, the regulation of inflammation and apoptosis is essential for mitigating organ dysfunction and treating associated malignancies. In this context, we will introduce a pyridine derivative with potent anti-fibrotic and anti-inflammatory properties – Hydronidone.
**Definition**
Hydronidone is an orally active pyridine derivative that acts as an inhibitor of phosphodiesterase-4 (PDE4), cyclo-oxygenase (COX), and TGF-β.
**In Vitro and In Vivo Studies**
The Hydronidone description highlights its ability to induce mitochondrial dysfunction and trigger apoptosis, making it valuable for liver fibrosis, anti-inflammation, and Hydronidone Cancer studies. In terms of Hydronidone in vitro activity, treatment with 200-400 μM inhibits the activation of HSCs and reduces liver fibrosis by regulating Smad7 expression. Specifically, at 400 μM, it promotes the degradation of TGFβRI via a Smad7-dependent ubiquitin-proteasome pathway. In LX-2 cells, Hydronidone (400 μM, 24 h) significantly promotes apoptosis through the intrinsic mitochondrial pathway, evidenced by increased Bax expression, decreased Bcl-2 expression, and the flow of cytochrome c from the mitochondria to the cytoplasm. Furthermore, it triggers endoplasmic reticulum stress (ERS), activating the IRE1α-ASK1-JNK pathway, as shown by upregulated Bip and phosphorylated IRE1α, ASK1, and JNK.
Regarding Hydronidone in vivo efficacy, administration of 50-100 mg/kg via oral gavage in mice models induced by carbon tetrachloride (CCl4) or 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) significantly ameliorates liver fibrosis and hepatic injury. These results are characterized by reduced collagen fiber content, decreased hepatic hydroxyproline levels, and the downregulation of fibrosis-related genes including Acta2, Col1a1, Col3a1, Mmp9, and Timp1. Additionally, it reduces α-SMA and Col1 levels in liver tissues while upregulating Smad7 protein expression. In conclusion, Hydronidone is a multi-target inhibitor that effectively suppresses HSC activation and promotes the apoptosis of activated HSCs to alleviate liver fibrosis.
Keywords
Hydronidone, 851518-71-3, Apoptosis, Mitochondrial Metabolism, Phosphodiesterase (PDE), TGF-beta/Smad, COX, Transforming growth factor beta, Cyclooxygenase, antifibrotic, agent, hepatic fibrosis, pyridine derivative, anti-inflammation, anti-cancer
References
[1] Xu X, et al. Hydronidone ameliorates liver fibrosis by inhibiting activation of hepatic stellate cells via Smad7-mediated degradation of TGFβRI. Liver Int. 2023 Nov;43(11):2523-2537.
[2] Sun Z, et al. Hydronidone induces apoptosis in activated hepatic stellate cells through endoplasmic reticulum stress-associated mitochondrial apoptotic pathway. J Gastroenterol Hepatol. 2024 Aug;39(8):1695-1703.
[3] Juillerat-Jeanneret L, et al. Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction. J Med Chem. 2018 Nov 21;61(22):9811-9840.
**Background**
Interferon-gamma (IFN-γ) is a critical pro-inflammatory cytokine that plays a pivotal role in innate and adaptive immunity. It is primarily produced by T cells and natural killer (NK) cells, where it regulates the expression of MHC molecules and activates macrophages. While essential for host defense against intracellular pathogens, dysregulated IFN-γ signaling is implicated in various pathological conditions, including chronic inflammation, autoimmune diseases, and certain malignancies. In the context of Anti-Mouse IFN gamma Antibody cancer research, modulating IFN-γ activity has become a key strategy for understanding tumor progression and immune-mediated tissue damage. Therefore, we will introduce a potent neutralizing agent – Anti-Mouse IFN gamma Antibody.
**Definition**
Anti-Mouse IFN gamma Antibody (XMG1.2) is a rat-derived IgG1 kappa antibody inhibitor designed to target and neutralize IFN-γ. According to the Anti-Mouse IFN gamma Antibody description, this antibody is used to block the biological activity of IFN-γ in both in vitro and in vivo experimental settings.
**In Vitro and In Vivo Studies**
The Anti-Mouse IFN gamma Antibody biological activity has been extensively validated across multiple disease models. In vitro, the antibody is suitable for applications including ELISPOT, flow cytometry, and Western blot to monitor IFN-γ levels and signaling. In vivo studies have demonstrated its efficacy in several challenging models. In multiple myeloma mice models, administration of 500 μg (i.p. at days 0, 3, 7, 10, 14, 17) increased serum IgG2b levels, increased the percentage of mice with progressive disease, and elevated both bone marrow and splenic tumor burdens. In paraneoplastic cerebellar degeneration models, 100 μg (i.p. every other day from day 10) protected mice from weight loss and motor performance decline, while preventing T cell-mediated Purkinje cell death and inhibiting T cell accumulation in the cerebellum. Furthermore, in LPS-induced macrophage activation syndrome models, a single i.p. dose of 100 µg/g significantly increased survival rates (70% survival with 7.5 µg/g LPS and 100% survival with 5 µg/g LPS), while increasing fibrinogen levels and decreasing IL-6 and ALT levels. Additionally, the antibody improved engraftment in Bacillus Calmette-Guerin-infected Ifngr1 -/- mice when administered at 100 mg/kg (i.v. after 14, 20, 28, 35, and 42 days). In conclusion, Anti-Mouse IFN gamma Antibody is a powerful tool for neutralizing IFN-γ to study chronic inflammation and cancer.
Keywords
Anti-Mouse IFN gamma Antibody (XMG1.2), IFNAR, Interferon-α/β receptor, Interferon-alpha/beta receptor, IFN-γ, Cancer, Inflammation, Immunology, Multiple myeloma, Chronic inflammation, Purkinje cell, Macrophage, Inhibitor, inhibitor, inhibit
References
[1] Kellermayer Z, et al. Interferon gamma-mediated prevention of tumor progression in a mouse model of multiple myeloma. Hemasphere. 2024 Dec 2;8(12):e70047.
[2] Prencipe, G., et al. Neutralization of Interferon-gamma is efficacious in a mouse model of HLH secondary to chronic inflammation. Pediatr Rheumatol 13 (Suppl 1), O29 (2015).
[3] Merli P, et al. Role of interferon-γ in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation. Haematologica. 2019 Nov;104(11):2314-2323.
[4] Yshii L, et al. IFN-γ is a therapeutic target in paraneoplastic cerebellar degeneration. JCI Insight. 2019 Apr 4;4(7):e127001.
[5] Prencipe G, et al. Neutralization of IFN-γ reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. J Allergy Clin Immunol. 2018 Apr;141(4):1439-1449.
**Background**
Insect juvenile hormones play a critical role in regulating the development and metamorphosis of insects, specifically by controlling the transition between larval, pupal, and adult stages. Disrupting these hormonal pathways is a primary strategy in the development of effective insecticides to control agricultural pests and disease vectors. Beyond entomology, recent pharmacological research has identified unexpected interactions between certain hormone analogs and mammalian G-protein coupled receptors. Specifically, the cannabinoid receptor type 1 (CB1) is a key target in the central nervous system and peripheral tissues, making the discovery of novel ligands essential for understanding receptor modulation. In this context, we will introduce an insect juvenile hormone analog that also acts as a CB1 receptor ligand – S-Methoprene.
**Definition**
S-Methoprene is an insect juvenile hormone analog and effective insecticide that blocks the transition from pupa to adult, which also functions as a CB1 receptor ligand with a Ki of 2.13 μM.
**In Vitro and In Vivo Studies**
According to the S-Methoprene description, this compound possesses a molecular weight of 310.47 and the S-Methoprene formula is C19H34O3. In terms of S-Methoprene biological activity, the compound has been utilized as a larvicide and to accelerate sexual maturation in male Queensland Fruit Flies (Diptera: Tephritidae). In vitro studies focusing on the CB1 receptor demonstrated that S-Methoprene inhibits the binding of the CB1 receptor antagonist [3H]CP-55940 to the CB1 receptor with an IC50 of 19.31 μM. Specifically, S-Methoprene (4 μM) inhibited [3H]CP-55940 binding by 27.32± 4.11% and 28.16± 4.17% in the absence and presence of 50 μM PMSF, respectively, in mouse meninges. Furthermore, S-Methoprene was found to inhibit CP-55940-stimulated binding of [35S]GTPγS to mouse meninges, demonstrating a concentration-dependent inhibition of CB1 receptor binding. In conclusion, S-Methoprene is a versatile compound that serves as both a potent insect growth regulator and a ligand for the mammalian CB1 receptor.
Keywords
S-Methoprene, 65733-16-6, (+)-Methoprene, (7S)-Methoprene, Cannabinoid Receptor, CB1 receptor, Sanguinarine, Chelerythrine, Piperonyl butoxide, Methoprene, Mouse brain, Inhibitor, inhibitor, inhibit
References
[1] Adnan SM, et al. Accelerated Sexual Maturation in Methoprene-Treated Sterile and Fertile Male Queensland Fruit Flies (Diptera: Tephritidae), and Mosquito Larvicide as an Economical and Effective Source of Methoprene. J Econ Entomol. 2019 Dec 9;112(6):2842-2849.
[2] Dhopeshwarkar AS, et al. The actions of benzophenanthridine alkaloids, piperonyl butoxide and (S)-methoprene at the G-protein coupled cannabinoid CB₁ receptor in vitro. Eur J Pharmacol. 2011 Mar 1;654(1):26-32.
**Background**
Nicotinamide adenine dinucleotide (NAD) is a critical cofactor and homeostatic regulator essential for cellular energy metabolism and redox balance. It serves as a key electron carrier, being reduced to NADH during the oxidation of organic substrates to indirectly generate ATP within the mitochondria. Due to its fundamental role in maintaining cellular health, NAD deficiency is linked to various metabolic disorders, including obesity, glucose intolerance, and non-alcoholic fatty liver disease. Furthermore, restoring NAD levels has shown potential in mitigating cellular stress and protecting tissues from injury. In this context, we will introduce a high-quality cofactor for biomedical research – NAD.
**Definition**
NAD (sodium) is an orally effective cofactor and homeostatic regulator with the molecular formula C21H26N7NaO14P2. It acts as a precursor to NADH and is utilized in research focusing on metabolic homeostasis and tissue repair.
**In Vitro and In Vivo Studies**
The NAD biological activity has been extensively characterized across various cell lines and animal models. In vitro studies demonstrate that NAD (sodium) is transported into NIH-3T3, SH-SY5Y, HeLa, HaCaT, HMEC, and RAW 264.7 cells, with an apparent Km of ~190 μM in NIH-3T3 cells. Specifically, NAD (sodium) (100 μM; 72 h) rescues FK866-induced cell death and replenishes intracellular NAD(P) levels in both NIH-3T3 and SH-SY5Y cells. Furthermore, treatment with 100 μM NAD (sodium) for 36 h was found to revert FK866-induced NAD autophagy in SH-SY5Y cells. In RAW264.7 cells, NAD (sodium) (0.5 mM) promotes M2 macrophage polarization, inhibits M1 polarization, and restores pro-angiogenic VEGF165 expression while inhibiting anti-angiogenic VEGF165b expression. Additionally, it restores reduced SRSF1 expression and inhibits increased SRSF6 expression in high glucose-exposed cells.
NAD in vivo studies have highlighted its therapeutic potential in cardiac recovery. In Kunming mice induced with diabetes and myocardial infarction, the administration of NAD+ (500 mg/kg/day; i.p.; daily for at least 28 days) significantly attenuated cardiac injury. This treatment restored cardiac NAD+ levels, reduced infarct size, and improved cardiac function, as evidenced by the reinstatement of ejection fraction (EF) and fractional shortening (FS) values. Moreover, it enhanced angiogenesis by increasing microvessel density and CD31/VEGF expression, while promoting M2 macrophage polarization in cardiac tissue. In conclusion, NAD is a versatile cofactor that supports cellular viability and promotes tissue regeneration in metabolic and cardiovascular disease models.
Keywords
NAD, 20111-18-6, β-DPN, β-NAD, β-Nicotinamide Adenine Dinucleotide, Endogenous Metabolite, 辅酶因子, 巨噬细胞M2极化诱导剂, Inhibitor, inhibitor, inhibit
References
[1] Rajman L, et al. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab. 2018;27(3):529-547.
[2] 20260224132312.pdf
[3] Ruszkiewicz J, et al. NAD+ Acts as a Protective Factor in Cellular Stress Response to DNA Alkylating Agents. Cells. 2023;12(19):2396. Published 2023 Oct 2.
[4] Jiao L, et al. NAD+ attenuates cardiac injury after myocardial infarction in diabetic mice through regulating alternative splicing of VEGF in macrophages. Vascul Pharmacol. 2022;147:107126.
**Background**
Familial hypercholesterolemia and various malignancies, including colorectal cancer and melanoma, present significant challenges in clinical medicine due to their complex metabolic and signaling pathways. The microsomal triglyceride transfer protein (MTP) and the mechanistic target of rapamycin complex 1 (mTORC1) are critical regulators of lipid metabolism and cell growth, respectively. Dysregulation of these targets often leads to elevated plasma LDL levels or uncontrolled tumor proliferation. Furthermore, neuroinflammation and oxidative stress play pivotal roles in the progression of cerebral ischemia/reperfusion injury. Given the need for agents that can modulate these diverse pathways, there is significant research interest in compounds with multi-target activity. In this context, we will introduce a versatile inhibitor – Lomitapide.
**Definition**
Lomitapide mesylate is an orally active MTP inhibitor and a selective mTORC1 inhibitor that exhibits lipid-lowering activity, blood-brain barrier (BBB) permeability, and HDAC inhibitory properties.
**In Vitro and In Vivo Studies**
According to the Lomitapide description, this compound acts as an ATP-competitive inhibitor of mTORC1, inducing AMPK-independent autophagic cell death. In terms of Lomitapide in vitro activity, Lomitapide mesylate (5 μM; 48 h) inhibits the proliferation of human HCT116, HT29, and SW480 colorectal cancer cells by reducing colony formation. It further induces autophagic cell death in HCT116 and HT29 cells (5 μM; 24 h), a process that can be reversed by autophagy inhibition. In patient-derived colorectal cancer organoids (CRC-01 and CRC-02), it potently inhibits growth (5-20 μM; 48-72 h), showing superior efficacy compared to 5-FU. Additionally, it provides neuroprotection by improving the survival rate of OGD-injured Neuro-2a cells and primary mouse cortical neurons (0.01-1 μM; 24 h) in a concentration-dependent manner.
Lomitapide in vivo studies demonstrate its broad therapeutic potential. In BALB/c nude mice, Lomitapide (10-50 mg/kg; i.p.; every 2 days for 10 days) potently inhibits colorectal cancer xenografts; at 20 mg/kg, HT29 tumor volume is reduced to 38% of the control. In C57B6/N mice, it inhibits MC38 colorectal cancer and B16-F10 melanoma growth (20 mg/kg; i.p.) while increasing CD8+ T cell infiltration. For neurological research, Lomitapide (0.5 mg/kg; p.o.; daily for 14 days) improves neurological function and reduces neuronal tissue loss by 41.05% in MCAO-induced ischemic stroke models. Furthermore, in obese LDLr−/− mice, oral administration (1 mg/kg/day; 2 weeks) improves cardiovascular function and reduces atherosclerotic plaque area. In conclusion, Lomitapide is a multi-functional agent that promotes Lomitapide Autophagy and inhibits lipid secretion, making it a valuable tool for cancer, stroke, and hypercholesterolemia research.
Keywords
Lomitapide, 202914-84-9, AEGR-733, BMS-201038, AEGR733, AEGR 733, BMS201038, BMS 201038, Microsomal Triglyceride Transfer Protein (MTP), mTOR, LDLR, Autophagy, Apoptosis, Mammalian target of Rapamycin, Low-density lipoprotein receptor
References
[1] Lee B, et al. Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR. Cell Death Dis. 2022;13(7):603. Published 2022 Jul 12.
[2] Zheng Y, et al. Lomitapide ameliorates middle cerebral artery occlusion-induced cerebral ischemia/reperfusion injury by promoting neuronal autophagy and inhibiting microglial migration. CNS Neurosci Ther. 2022;28(12):2183-2194.
[3] Munkhsaikhan U, et al. The Beneficial Effect of Lomitapide on the Cardiovascular System in LDLr-/- Mice with Obesity. Antioxidants (Basel). 2023;12(6):1287. Published 2023 Jun 16.
[4] Won JI, et al. Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia. Rev Cardiovasc Med. 2017;18(1):21-28.
**Background**
Colorectal cancer (CRC) remains one of the most prevalent and lethal malignancies worldwide, characterized by high recurrence rates and complex signaling pathways. Signal transducer and activator of transcription 3 (STAT3) is frequently overactivated in various cancers, including CRC, where it promotes cell survival, proliferation, and resistance to apoptosis. Consequently, targeting the STAT3 signaling axis has become a primary focus for developing novel therapeutic strategies to inhibit tumor growth. Beyond traditional chemotherapy, the repurposing of anthelmintic drugs has revealed significant potential in oncology. In this context, we will introduce an antitumor agent with potent inhibitory effects on STAT3 and microtubule function – Flubendazole.
**Definition**
Flubendazole is an anthelmintic and antitumor drug that acts by altering microtubule structure and inhibiting tubulin polymerization. It functions as a STAT3 inhibitor, effectively inducing apoptosis and autophagy in various cancer cell lines.
**In Vitro and In Vivo Studies**
According to the Flubendazole description, this compound exerts its effects by blocking the STAT3 signaling axis and inducing P53 expression while reducing Cyclin B1 and p-cdc2 expression. Flubendazole in vitro studies have demonstrated significant efficacy across multiple cell lines. In human CRC cells (HCT116, RKO, and SW480), Flubendazole (0-400 μM; 48 h) inhibited cell proliferation with IC50 values ranging from 2-5 μM. Furthermore, concentrations of 0.3-1.2 μM over 48 hours increased the proportion of apoptotic cells and enhanced caspase-3 activity. Notably, Flubendazole Autophagy was observed at concentrations of 0.3-1.2 μM (24 h), where it initiated autophagy by inactivating mTOR and P62 and upregulating LC3-I/II. Western blot analysis confirmed a dose- and time-dependent reduction of phosphorylated STAT3 (P-STAT3) and decreased expression of MCL1 and survivin. Additionally, the compound showed potent anticancer activity against BT-549 (IC50 = 0.125 μM), Hs-578T (IC50 = 0.125 μM), and MDA-MB-231 (IC50 = 0.25-0.75 μM) cells.
Flubendazole in vivo research using female BALB/c athymic nude mice bearing HCT116 xenografts showed that administration of 10 or 30 mg/kg via intraperitoneal injection every other day for 14 days markedly reduced tumor volume. These results were associated with a significant reduction in P-STAT3 protein levels and the promotion of apoptosis and autophagy within the tumor tissue. In conclusion, Flubendazole is a versatile antitumor agent that inhibits tumor growth by targeting the STAT3 pathway and disrupting microtubule function.
Keywords
Flubendazole, 31430-15-6, Parasite, Microtubule/Tubulin, STAT, MDM-2/p53, Apoptosis, Autophagy, Anthelmintic, microtubule, tubulin polymerization, CRC, Cyclin B1, p-cdc2, worm, intestinal parasites, colorectal cancer, Inhibitor, inhibitor, inhibit
References
[1] Zhou X, et al. Flubendazole inhibits glioma proliferation by G2/M cell cycle arrest and pro-apoptosis. Cell Death Discov. 2018 Feb 14;4:18.
[2] Shichong Lin, et al. Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy. J Exp Clin Cancer Res. 2019 Jul 8;38(1):293.
**Background**
Cancer metastasis, the process by which tumor cells spread from the primary site to distant organs, is a major cause of mortality in cancer patients. This complex process relies heavily on the reorganization of the actin cytoskeleton to facilitate cell migration and invasion. The actin-related protein 2/3 (Arp2/3) complex plays a pivotal role in this process by nucleating branched actin filaments, which are essential for the formation of lamellipodia and the movement of cancer cells. Specifically, the actin-related protein 2/3 complex subunit 2 (ARPC2) is a critical component of this machinery. Targeting the Arp2/3 complex offers a promising strategy to suppress the invasive potential of malignant cells. In this context, we will introduce an ARPC2 inhibitor – Benproperine.
**Definition**
Benproperine phosphate is an orally active and potent ARPC2 inhibitor that attenuates the actin polymerization rate by impairing the function of the Arp2/3 complex.
**In Vitro and In Vivo Studies**
The Benproperine description highlights its dual potential as a cough suppressant and an agent to suppress cancer cell migration. Regarding Benproperine in vitro activity, studies demonstrated that Benproperine phosphate (20-120 μM; 24 hours) inhibits cell viability in a dose-dependent manner across various cancer cell lines, including DLD-1, AsPC-1, CFPAC-1, A375P, MDA-MB-231, and DU145. Furthermore, at a concentration of 10 μM for 24 hours, it significantly inhibits the migration of multiple cancer cell types, specifically inhibiting the migration and invasion of DLD-1 and AsPC-1 cells with IC50 values of 1-2 μM. Notably, it does not affect the cortactin-rich lamellipodium in MCF-10A cells.
The Benproperine in vivo efficacy has been further validated in animal models. In female BALB/c nude mice bearing AsPC-1 cells, Benproperine phosphate (50, 100 mg/kg; oral gavage; 5 days per week for 4 weeks) inhibited primary pancreatic tumor growth by 47.7% compared to the vehicle control, without causing changes in body weight. Additionally, Benproperine phosphate showed a marked decrease in lung metastasis of AsPC-1 cells (56.1% inhibition) and significantly suppressed liver metastasis of HCT-116 cells by 78.9% and DLD-1 cells by 78.2%. In conclusion, Benproperine is a potent ARPC2 inhibitor that suppresses Benproperine Cancer progression by inhibiting cell migration and tumor metastasis.
Keywords
Benproperine, 19428-14-9, Arp2/3 Complex, Actin-related protein 2/3 complex, orally, actin-related, protein, 2/3, complex, subunit, ARPC2, polymerization, rate, cough, migration, metastasis, DLD-1, AsPC-1, CFPAC-1, A375P, MDA-MB-231, DU145, Inhibitor, inhibitor, inhibit
References
The mechanical stability and degradation kinetics of injectable PCL-PEG-PCL-gelatin (Gel) and PCL-PEG-PCL-Gel/nano-hydroxyapatite (nHA) hydrogels were evaluated in a mouse subcutaneous implantation model over a 14-day period. The hydrogels were fabricated via in situ precipitation and implanted at the supraflank region. At day 14 post-implantation, the scaffolds were retrieved for morphological and compositional analysis.
Bright-field imaging revealed complete biodegradation of both PCL-PEG-PCL and PCL-PEG-PCL-Gel hydrogels, with no residual material detectable beneath the dermal layer. In contrast, small fragments of PCL-PEG-PCL-Gel/nHA hydrogel remained visible at the implant site, indicating significantly delayed degradation. This prolonged persistence is attributed to the reinforcing effect of nHA nanoparticles, which enhance crosslinking density and resist enzymatic and hydrolytic breakdown.CD79B Antibody Epigenetics
Rheological measurements confirmed this trend: the storage modulus (G′) and loss modulus (G″) of the PCL-PEG-PCL-Gel/nHA hydrogel were consistently higher than those of the Gel-only variant across all tested frequencies (10–100 rad/s). At 37°C, G′ values reached approximately 2.8 × 10⁴ Pa for the nHA-containing scaffold versus 1.9 × 10⁴ Pa for PCL-PEG-PCL-Gel, reflecting superior structural integrity and resistance to deformation. The enhanced mechanical performance is further supported by SEM images showing a more stable porous architecture with intact interconnections after implantation.RITA Apoptosis
Degradation was also assessed through histological evaluation of the surrounding tissue.PMID:35203867 While the control and Gel-only groups showed complete absorption with minimal fibrous encapsulation, the nHA-containing group exhibited partial retention of scaffold remnants surrounded by mild granulation tissue, consistent with slow resorption. No signs of acute necrosis, calcification, or foreign body giant cell formation were observed, confirming that the residual material did not trigger adverse reactions.
These findings demonstrate that the addition of nano-hydroxyapatite effectively modulates the degradation profile of PCL-PEG-PCL-Gel hydrogels, extending their residence time without compromising biocompatibility. This extended durability allows sustained delivery of bioactive signals and provides mechanical support during early tissue regeneration phases—critical for applications in load-bearing bone repair.
In summary, PCL-PEG-PCL-Gel/nHA hydrogels exhibit tunable degradation behavior, combining long-term stability with safe clearance, making them ideal candidates for regenerative therapies requiring controlled, prolonged scaffold function.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com
Droplet-based printing techniques have enabled the fabrication of a diverse array of flexible physical sensors capable of monitoring physiological signals with high sensitivity and reliability. These devices are revolutionizing healthcare by enabling continuous, non-invasive, and remote health monitoring, shifting medical care from hospitals to homes. The integration of printed electronics into wearable and implantable platforms has paved the way for real-time tracking of vital signs such as pulse rate, body temperature, respiratory patterns, muscle contractions, and gastrointestinal activity.
Inkjet-printed polymer-based temperature sensors using PEDOT:PSS on lyophilic substrates demonstrate stable performance across −15°C to 80°C with a thermal coefficient of resistance (TCR) of −0.75%/°C. Inductive position sensors fabricated with silver coils on polyimide substrates exhibit precise impedance changes in response to angular displacement, making them suitable for motion detection in prosthetics and robotics. Strain sensors based on PEDOT:PSS and graphene–zinc oxide nanocomposites show linear resistance changes under tensile strain, with sensitivities reaching up to 0.73 ± 0.1 per percent strain. Notably, graphene–ZnO composites with optimized blending ratios achieve superior stretchability and repeatability, demonstrating potential for use in smart garments and electronic skin.
Aerosol jet printing has proven effective for high-resolution strain and pressure sensing on complex geometries. Silver nanoparticle-based strain gauges printed on carbon fiber pre-pregs exhibit a gauge factor (GF) of 2.2 ± 0.06 and excellent mechanical durability, passing interlaminar shear strength tests. CNT-based sensors on resin-coated substrates display high sensitivity, with one device achieving a GF of 1.7. Triboelectric motion sensors fabricated via aerosol jet printing utilize fine-grating electrodes on Kapton substrates, generating open-circuit voltages proportional to sliding speed—reaching sensitivities of up to 630 µV/µm. Integrated capacitive touch sensors have also been successfully printed on 3D curved substrates, responding reliably to finger contact and enabling interactive wearable interfaces.
Electrohydrodynamic jet printing enables ultra-high-resolution sensors with sub-100 nm features. E-jet printed temperature sensors using silver nanoparticle ink on nanocellulose substrates achieve a TCR of 0.06%/°C, suitable for artificial skin applications.Adenosine receptor antagonist 2 Biological Activity Capacitive touch sensors with comb-like interdigital structures show a capacitance change of ~0.9 pF upon single-finger touch, demonstrating fast response and high signal-to-noise ratio. Flexible piezoresistive pressure sensors based on CNT–polyimide composites exhibit high sensitivity, with some devices achieving a GF of 5.1-(Cyclopropylcarbonyl)piperazine manufacturer 7 ± 0.PMID:35134806 3 at 1.8 wt% CNT concentration. Others, like those using microstructured PDMS dielectrics, show high sensitivity below 70 Pa (10.4 kPa⁻¹), though sensitivity drops significantly at higher pressures.
Notable advancements include bimodal sensors that simultaneously detect strain and pressure. One all-inkjet-printed sensor combines a microcrack-based strain sensing mechanism with a capacitive pressure response, achieving a strain GF of 4000 and a pressure detection limit of just 2 Pa. Au-nanowire-based pressure sensors integrated with wireless transmitters enable real-time data transmission, showing high repeatability over 10,000 cycles. Piezoelectric sensors using P(VDF-TrFE) copolymers generate output voltages of ~250 mV under human fingertip pressure, highlighting their potential for self-powered wearable systems.
These sensors are not limited to laboratory demonstrations. They are being deployed in clinical settings for early disease detection, rehabilitation monitoring, and elderly care. Their low cost, scalability, and compatibility with unconventional substrates make them ideal for mass production and point-of-care diagnostics. As these technologies mature, they will become integral components of the Internet of Things, enabling intelligent, adaptive, and personalized healthcare ecosystems. By combining advanced materials, precision printing, and smart data processing, droplet-based sensors are poised to transform how we monitor and manage health in everyday life.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com